Modeling the impact of novel TB drug regimens and drug susceptibility tests

Location

Baltimore, Maryland, US

Dates

04/01/2013 - 06/01/2015

PI

David Dowdy, MD, PhD, ScM

We are constructing mathematical models of TB epidemics in Southeast Asia, India, and Vietnam to explore the potential population-level impact of drug susceptibility testing and novel TB drug regimens including PaMZ on the epidemic of MDR TB.

Projects

ACTG trial A5343

Phase 2 safety study of bedaquiline and delamanid for the treatment of MDR-TB in South Africa

Read More

Statins as adjunctive host-directed therapy...

This study will investigate the role of statins in combination with the first-line regimen for TB in the mouse model. In...

Read More

Assessing the social value of novel regimens...

We are collaborating with investigators from the Berman Bioethics Institute to develop novel techniques for economic evaluation...

Read More

Modeling the impact of spatially targeted TB...

 We have developed transmission models to understand the impact of TB vaccination strategies that target hotspots of...

Read More